• +1-646-491-9876
    • +91-20-67278686

    Search

    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016

    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016

    • Report Code ID: RW0001513515
    • Category Pharmaceuticals
    • No. of Pages 48
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016

    Summary

    Publisher's, 'TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Review, H2 2016', provides in depth analysis on TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted pipeline therapeutics.

    The report provides comprehensive information on the TAR DNA Binding Protein 43 (TDP43 or TARDBP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for TAR DNA Binding Protein 43 (TDP43 or TARDBP)
    - The report reviews TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics and enlists all their major and minor projects
    - The report assesses TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to TAR DNA Binding Protein 43 (TDP43 or TARDBP) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for TAR DNA Binding Protein 43 (TDP43 or TARDBP)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding TAR DNA Binding Protein 43 (TDP43 or TARDBP) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents

    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) Overview 6
    Therapeutics Development 7
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Stage of Development 7
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Therapy Area 8
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Indication 9
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Pipeline Products Glance 10
    Late Stage Products 10
    Early Stage Products 11
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Products under Development by Companies 12
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Therapeutics Assessment 14
    Assessment by Monotherapy/Combination Products 14
    Assessment by Mechanism of Action 15
    Assessment by Route of Administration 16
    Assessment by Molecule Type 17
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Companies Involved in Therapeutics Development 19
    Biogen Inc 19
    ImStar Therapeutics Inc. 20
    Primary Peptides, Inc. 21
    SK Biopharmaceuticals Co Ltd 22
    TauRx Therapeutics Ltd 23
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Drug Profiles 24
    IMS-088 - Drug Profile 24
    Product Description 24
    Mechanism Of Action 24
    R&D Progress 24
    NI-205 - Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 26
    Product Description 26
    Mechanism Of Action 26
    R&D Progress 26
    Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 27
    Product Description 27
    Mechanism Of Action 27
    R&D Progress 27
    Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    TRx-0237 - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Dormant Projects 34
    TAR DNA Binding Protein 43 (TDP43 or TARDBP) - Featured News & Press Releases 35
    Sep 04, 2016: TRx-237-007 Phase 3 Clinical Trial Update 35
    Jul 27, 2016: TauRx Reports First Phase 3 Results for LMTX 35
    Jul 22, 2016: TauRx Phase 3 Trial TRx-237-007 in behavioural variant frontotemporal dementia 37
    Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS 37
    Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease 38
    Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy 39
    Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease 40
    Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer's Disease 42
    Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia 43
    Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments 43
    Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th 44
    Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease 44
    Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States 45
    Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS 45
    Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer's Disease at annual psychogeriatric conference in Korea 46
    Appendix 47
    Methodology 47
    Coverage 47
    Secondary Research 47
    Primary Research 47
    Expert Panel Validation 47
    Contact Us 47
    Disclaimer 48

    List of Tables

    Number of Products under Development for, H2 2016 7
    Number of Products under Development by Therapy Area, H2 2016 8
    Number of Products under Development by Indication, H2 2016 9
    Comparative Analysis by Late Stage Development, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 11
    Number of Products under Development by Companies, H2 2016 12
    Products under Development by Companies, H2 2016 13
    Assessment by Monotherapy/Combination Products, H2 2016 14
    Number of Products by Stage and Mechanism of Action, H2 2016 15
    Number of Products by Stage and Route of Administration, H2 2016 16
    Number of Products by Stage and Molecule Type, H2 2016 18
    Pipeline by Biogen Inc, H2 2016 19
    Pipeline by ImStar Therapeutics Inc., H2 2016 20
    Pipeline by Primary Peptides, Inc., H2 2016 21
    Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 22
    Pipeline by TauRx Therapeutics Ltd, H2 2016 23
    Dormant Projects, H2 2016 34

    List of Figures

    Number of Products under Development for, H2 2016 7
    Number of Products under Development by Indication, H2 2016 9
    Comparative Analysis by Late Stage Development, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 11
    Assessment by Monotherapy/Combination Products, H2 2016 14
    Number of Products by Stage and Mechanism of Actions, H2 2016 15
    Number of Products by Stage and Routes of Administration, H2 2016 16
    Number of Products by Molecule Types, H2 2016 17
    Number of Products by Stage and Molecule Type, H2 2016 17
    Biogen Inc
    ImStar Therapeutics Inc.
    Primary Peptides, Inc.
    SK Biopharmaceuticals Co Ltd
    TauRx Therapeutics Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//tar-dna-binding-protein-43-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//tar-dna-binding-protein-43-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//tar-dna-binding-protein-43-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments